New COPD Drug Reduces Flare-Ups by 34% in Smokers

Nearly 16 million Americans struggle to breathe every day because of COPD, a group of incurable lung diseases that kills over 138,000 people annually. Now, a new medication called tozorakimab is giving patients genuine hope for relief.

Late-stage clinical trials revealed that the drug reduced moderate and severe COPD flare-ups by 29% to 34% in former smokers and current smokers alike. The injectable medication, given once every four weeks, works alongside standard inhaler treatments to help patients manage their symptoms more effectively.

What makes this breakthrough particularly exciting is who it can help. While some COPD medications already exist for patients with elevated blood eosinophil levels, tozorakimab would become the first biologic option for COPD patients with lower eosinophil counts if approved. That opens the door for treatment to a much broader population of patients who previously had limited options.

Dr. Frank Sciurba, professor of pulmonary and critical care medicine at the University of Pittsburgh, called it the first biologic drug to show effectiveness in treating COPD symptoms across a wide range of patients. The results were presented at the European Respiratory Society Congress and will be published in a peer-reviewed journal.

The drug targets interleukin-33, a protein released by damaged cells that triggers inflammation in conditions like COPD. By blocking this protein, tozorakimab both decreases inflammation and disrupts the cycle of mucus dysfunction that makes breathing so difficult for COPD patients.

Aside from minor reactions at the injection site, patients tolerated the medication well without significant side effects. This safety profile, combined with its effectiveness, helped earn the drug priority review status from the FDA, meaning regulators will fast-track their evaluation for approval.

The Ripple Effect

This breakthrough reaches far beyond individual patients. While tobacco smoke causes most COPD cases in the U.S., one in four patients with the disease never smoked at all. Many developed COPD from secondhand smoke, workplace exposures, or genetic factors beyond their control.

The new treatment offers hope to all these patients, regardless of their smoking history. For families watching loved ones struggle with an incurable disease, tozorakimab represents something precious: the possibility of more good days, fewer hospital visits, and more time together.

AstraZeneca, the pharmaceutical company developing the drug, is already investigating whether tozorakimab could help patients with asthma and other lower respiratory tract diseases. The same mechanism that helps COPD patients might bring relief to millions more people with different breathing conditions.

With COPD ranking among the top 10 leading causes of death in America, any meaningful progress matters deeply.